DUSA Pharmaceuticals
This article was originally published in The Gray Sheet
Executive Summary
Maker of Levulan photodynamic therapy and photodetection products receives FDA "approvable" letter for a PMA supplement for a commercial version of its BLU-U light source for use in conjunction with the Levulan Kerastick actinic keratoses therapy for the face and scalp. A BLU-U prototype gained approval in December 1999 in conjunction with a new drug application for Levulan (1"The Gray Sheet" Dec. 13, 1999, p. 17)
You may also be interested in...
DUSA Pharmaceuticals' Actinic Keratosis PDT Treatment Is Tip Of Pipeline
DUSA Pharmaceuticals plans to submit a premarket approval application supplement within the next two months for the commercial version of the firm's BLU-U light source used in conjunction with the Levulan Kerastick actinic keratoses therapy.
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.